Advertisement

Brain Metastases and Leptomeningeal Metastases

  • Lynn Mubita
  • Ian Lee
  • Mira Shah
  • Emilie Le Rhun
  • Steven KalkanisEmail author
Chapter

Abstract

This chapter explores the current consensus on the management and treatment of brain metastases and of leptomeningeal metastasis.

Keywords

Brain Cancer Neoplastic meningitis Leptomeningeal disease 

References

  1. 1.
    Cancer facts and figures. Statistics for 2017 [online resource] (2017) American Cancer Society, Atlanta. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html
  2. 2.
    Zimm S, Wampler GL, Stablein D et al (1981) Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 48(2):384–394CrossRefGoogle Scholar
  3. 3.
    Shaffrey ME, Mut M, Asher AL et al (2004) Brain metastases. Curr Probl Surg 41:665–741CrossRefGoogle Scholar
  4. 4.
    Glantz MJ, Cole BF, Forsyth PA et al (2000) Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 54(10):1886–1893CrossRefGoogle Scholar
  5. 5.
    Gaspar L, Scott C, Rotman M et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37(4):745–751CrossRefGoogle Scholar
  6. 6.
    Sperduto PW et al (2008) A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70(2):510–514CrossRefGoogle Scholar
  7. 7.
    Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA, Shih HA, Bangdiwala A, Shanley R, Lockney NA, Beal K, Lou E, Amatruda T, Sperduto WA, Kirkpatrick JP, Yeh N, Gaspar LE, Molitoris JK, Masucci L, Roberge D, Yu J, Chiang V, Mehta M (2017) Estimating survival in melanoma patients with brain metastases: an update of the graded prognostic assessment for melanoma using molecular markers (melanoma-molGPA). Int J Radiat Oncol Biol Phys 99(4):812–816CrossRefGoogle Scholar
  8. 8.
    Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, Shanley R, Yeh N, Gaspar LE, Braunstein S, Sneed P, Boyle J, Kirkpatrick JP, Mak KS, Shih HA, Engelman A, Roberge D, Arvold ND, Alexander B, Awad MM, Contessa J, Chiang V, Hardie J, Ma D, Lou E, Sperduto W, Mehta MP (2017) Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol 3(6):827–831CrossRefGoogle Scholar
  9. 9.
    Barker FG 2nd (2004) Craniotomy for the resection of metastatic brain tumors in the U.S., 1988–2000: decreasing mortality and the effect of provider caseload. Cancer 100:999–1007CrossRefGoogle Scholar
  10. 10.
    Patchell RA, Tibbs PA, Walsh JW et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322(8):494–500CrossRefGoogle Scholar
  11. 11.
    Vecht CJ, Haaxma-Reiche H, Noordijk EM et al (1993) Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 33(6):583–590CrossRefGoogle Scholar
  12. 12.
    Mintz AH, Kestle J, Rathbone MP et al (1996) A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 78(7):1470–1476CrossRefGoogle Scholar
  13. 13.
    Hart MG, Grant R, Walker M, Dickinson H (2005) Surgical resection and whole brain radiation therapy versus whole brain radiation therapy alone for single brain metastases. Cochrane Database Syst Rev (1):CD003292Google Scholar
  14. 14.
    Black PM, Johnson MD (2004) Surgical resection for patients with solid brain metastases: current status. J Neurooncol 69:119–124CrossRefGoogle Scholar
  15. 15.
    Paek SH, Audu PB, Sperling MR et al (2005) Reevaluation of surgery for the treatment of brain metastases: review of 208 patients with single or multiple brain metastases treated at one institution with modern neurosurgical techniques. Neurosurgery 56:1021–1034PubMedGoogle Scholar
  16. 16.
    Stark AM, Tscheslog H, Buhl R et al (2005) Surgical treatment for brain metastases: prognostic factors and survival in 177 patients. Neurosurg Rev 28:115–119CrossRefGoogle Scholar
  17. 17.
    Stea B, Suh JH, Boyd AP et al (2006) Whole-brain radiotherapy with or without efaproxiral for the treatment of brain metastases: determinants of response and its prognostic value for subsequent survival. Int J Radiat Oncol Biol Phys 64(4):1023–1030CrossRefGoogle Scholar
  18. 18.
    Meyers CA, Smith JA, Bezjak A et al (2004) Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22(1):157–165CrossRefGoogle Scholar
  19. 19.
    Ceresoli GL, Cappuzzo F, Gregorc V et al (2004) Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 15:1042–1047CrossRefGoogle Scholar
  20. 20.
    Liu R, Martuza RL, Rabkin SD (2005) Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain. Gene Ther 12:647–654CrossRefGoogle Scholar
  21. 21.
    Sampson JH, Carter JH Jr, Friedman AH, Seigler HF (1998) Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88(1):11–20CrossRefGoogle Scholar
  22. 22.
    Chapman PB, Hauschild A, Robert C et al (2011) BRIM-3 Study Group Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516CrossRefGoogle Scholar
  23. 23.
    Pease NJ, Edwards A, Moss LJ (2005) Effectiveness of whole brain radiotherapy in the treatment of brain metastases: a systematic review. Palliat Med 19(4):288–299CrossRefGoogle Scholar
  24. 24.
    Plotkin SR, Wen PY (2003) Brain metastases. In: Samuels MA, Feske SK (eds) Office practice of neurology, 2nd edn. Churchill Livingstone, Philadelphia, pp 1101–1106CrossRefGoogle Scholar
  25. 25.
    Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azambuja E, Henriksson R, Boulanger T, Peters S, Watts C, Wick W, Wesseling P, Rudà R, Preusser M, EANO Executive Board and ESMO Guidelines Committee (2017) EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol 28(Suppl 4):iv84–iv99.  https://doi.org/10.1093/annonc/mdx221 CrossRefPubMedGoogle Scholar
  26. 26.
    Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E, Moore B, Brisbane I, Ardron D, Holt T, Morgan S, Lee C, Waite K, Bayman N, Pugh C, Sydes B, Stephens R, Parmar MK, Langley RE (2016) Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet 388(10055):2004–2014CrossRefGoogle Scholar
  27. 27.
    Patchell RA, Tibbs PA, Regine WF et al (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280:1485–1489CrossRefGoogle Scholar
  28. 28.
    Maraveyas A, Sgouros J, Upadhyay S et al (2005) Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I study. Br J Cancer 92:815–819CrossRefGoogle Scholar
  29. 29.
    Cerchietti LC, Bonomi MR, Navigante AH et al (2005) Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases. J Neurooncol 71:73–81CrossRefGoogle Scholar
  30. 30.
    Kondziolka D, Niranjan A, Flickinger JC, Lunsford LD (2005) Radiosurgery with or without whole-brain radiotherapy for brain metastases: the patients’ perspective regarding complications. Am J Clin Oncol 28:173–179CrossRefGoogle Scholar
  31. 31.
    Tsao MN, Lloyd NS, Wong RK et al (2005) Radiotherapeutic management of brain metastases: a systematic review and meta-analysis. Cancer Treat Rev 31:256–273CrossRefGoogle Scholar
  32. 32.
    Lester JF, Macbeth FR, Coles B (2005) Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small-cell lung cancer: a Cochrane review. Int J Radiat Oncol Biol Phys 2005:23Google Scholar
  33. 33.
    Gore E, Choy H (2004) Non-small cell lung cancer and central nervous system metastases: should we be using prophylactic cranial irradiation? Semin Radiat Oncol 14:292–297CrossRefGoogle Scholar
  34. 34.
    Andrews DW, Scott CB, Sperduto PW et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomized trial. Lancet 363(9422):1665–1672CrossRefGoogle Scholar
  35. 35.
    O’Neill BP, Iturria NJ, Link MJ et al (2003) A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. Int J Radiat Oncol Biol Phys 55:1169–1176CrossRefGoogle Scholar
  36. 36.
    Chan TA, Weingart JD, Parisi M et al (2005) Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy. Int J Radiat Oncol Biol Phys 62:1133–1139CrossRefGoogle Scholar
  37. 37.
    Kokkoris CP (1983) Leptomeningeal carcinomatosis. How does cancer reach the pia-arachnoid? Cancer 51:154–160CrossRefGoogle Scholar
  38. 38.
    Glass JP, Melamed M, Chernik NL et al (1979) Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 29:1369–1375CrossRefGoogle Scholar
  39. 39.
    Boogerd W, Hart AAM, van der Sande JJ et al (1991) Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 67:1685–1695CrossRefGoogle Scholar
  40. 40.
    Bonneau C, Paintaud G, Trédan O, Dubot C, Desvignes C, Dieras V, Taillibert S, Tresca P, Turbiez I, Li J, Passot C, Mefti F, Mouret-Fourme E, Le Rhun E, Gutierrez M (2018) Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. Eur J Cancer 95:75–84.  https://doi.org/10.1016/j.ejca.2018.02.032. Epub 2018 Apr 7CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Lynn Mubita
    • 1
  • Ian Lee
    • 1
  • Mira Shah
    • 2
  • Emilie Le Rhun
    • 3
    • 4
    • 5
    • 6
  • Steven Kalkanis
    • 1
    Email author
  1. 1.Department of NeurosurgeryHenry Ford Health SystemDetroitUSA
  2. 2.Department of Radiation OncologyHenry Ford Health SystemDetroitUSA
  3. 3.Univ. Lille, U-1192LilleFrance
  4. 4.Inserm, U-1192LilleFrance
  5. 5.Neuro-oncology, Neurosurgery DepartmentCHU LilleLilleFrance
  6. 6.Neurology, Breast Cancer DepartmentOscar Lambret CenterLilleFrance

Personalised recommendations